Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.890
-0.210 (-5.12%)
Feb 4, 2026, 2:50 PM EST - Market open
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 800 employees as of December 31, 2024. The number of employees increased by 300 or 60.00% compared to the previous year.
Employees
800
Change
300
Growth
60.00%
Revenue / Employee
$54,611
Profits / Employee
-$894,429
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 800 | 300 | 60.00% |
| Sep 30, 2024 | 500 | -50 | -9.09% |
| Jun 30, 2024 | 500 | -50 | -9.09% |
| Mar 31, 2024 | 500 | 0 | - |
| Dec 31, 2023 | 500 | 0 | - |
| Sep 30, 2023 | 550 | 50 | 10.00% |
| Jun 30, 2023 | 550 | 100 | 22.22% |
| Mar 31, 2023 | 500 | 50 | 11.11% |
| Dec 31, 2022 | 500 | 100 | 25.00% |
| Sep 30, 2022 | 500 | 170 | 51.52% |
| Jun 30, 2022 | 450 | 180 | 66.67% |
| Mar 31, 2022 | 450 | 232 | 106.42% |
| Dec 31, 2021 | 400 | 69 | 20.85% |
| Sep 30, 2021 | 330 | -1 | -0.30% |
| Jun 30, 2021 | 270 | - | - |
| Mar 31, 2021 | 218 | - | - |
| Dec 31, 2020 | 331 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 1,372 |
| Ultragenyx Pharmaceutical | 1,294 |
| Ascentage Pharma Group International | 605 |
| Galapagos NV | 558 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
| Aurinia Pharmaceuticals | 130 |
| Olema Pharmaceuticals | 122 |
RXRX News
- 12 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript - Seeking Alpha
- 21 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - 3 Small AI Plays to Buy for 2026 - Benzinga
- 6 weeks ago - Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 - Seeking Alpha
- 6 weeks ago - What's Happening With RXRX Stock? - Forbes
- 2 months ago - Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript - Seeking Alpha
- 2 months ago - Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial - Reuters